Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JK08 |
Synonyms | |
Therapy Description |
JK08 comprises an anti-CTLA4 antibody fused to the IL-15/IL15Ralpha complex, which may result in T-cell activation and an increased anti-tumor immune response (Ann Oncol (2023) 34 (suppl_2): S635, Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JK08 | JK-08|JK 08 | CTLA4 Antibody 31 | JK08 comprises an anti-CTLA4 antibody fused to the IL-15/IL15Ralpha complex, which may result in T-cell activation and an increased anti-tumor immune response (Ann Oncol (2023) 34 (suppl_2): S635, Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |